Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal meningitis
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 18 Nov 2017 This trial has been completed in Finland (End Date:2017-10-26 ).
- 15 Nov 2017 This trail has been completed in Hungary (End date: 2017-10-26).
- 14 Nov 2017 Status changed from active, no longer recruiting to completed.